1. Home
  2. MOBI vs SPRY Comparison

MOBI vs SPRY Comparison

Compare MOBI & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobia Medical Inc. Common Stock

MOBI

Mobia Medical Inc. Common Stock

N/A

Current Price

$9.71

Market Cap

383.0M

Sector

Health Care

ML Signal

N/A

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$4.33

Market Cap

404.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOBI
SPRY
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.0M
404.8M
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
MOBI
SPRY
Price
$9.71
$4.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$17.75
★ $22.50
AVG Volume (30 Days)
217.6K
★ 1.4M
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $84,278,000.00
Revenue This Year
$71.88
$54.14
Revenue Next Year
$43.02
$46.73
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$8.45
$4.00
52 Week High
$15.19
$13.15

Technical Indicators

Market Signals
Indicator
MOBI
SPRY
Relative Strength Index (RSI) 45.89 40.49
Support Level $8.45 N/A
Resistance Level $11.55 $4.57
Average True Range (ATR) 0.81 0.25
MACD -0.00 0.05
Stochastic Oscillator 40.24 57.89

Price Performance

Historical Comparison
MOBI
SPRY

About MOBI Mobia Medical Inc. Common Stock

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: